[go: up one dir, main page]

DK1869020T3 - Heteroarylureaderivater egnet til inhibering af CHK1 - Google Patents

Heteroarylureaderivater egnet til inhibering af CHK1

Info

Publication number
DK1869020T3
DK1869020T3 DK06748900.5T DK06748900T DK1869020T3 DK 1869020 T3 DK1869020 T3 DK 1869020T3 DK 06748900 T DK06748900 T DK 06748900T DK 1869020 T3 DK1869020 T3 DK 1869020T3
Authority
DK
Denmark
Prior art keywords
heteroire
urea derivatives
derivatives suitable
inhibiting chk1
chk1
Prior art date
Application number
DK06748900.5T
Other languages
English (en)
Inventor
Francine S Farouz
Ryan Holcomb
Edward A Kesicki
Hua Chee Ooi
Alexander Rudolph
Frank Stappenbeck
Eugene Thorsett
John Joseph Gaudino
Adam Wade Cook
Frank Diaz
Kimba L Fisher
Original Assignee
Icos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icos Corp filed Critical Icos Corp
Application granted granted Critical
Publication of DK1869020T3 publication Critical patent/DK1869020T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
DK06748900.5T 2005-03-29 2006-03-29 Heteroarylureaderivater egnet til inhibering af CHK1 DK1869020T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66602605P 2005-03-29 2005-03-29
PCT/US2006/011584 WO2006105262A1 (en) 2005-03-29 2006-03-29 HETEROARYL UREA DERIVATIVES USEFUL FOR INHIBITING CHKl

Publications (1)

Publication Number Publication Date
DK1869020T3 true DK1869020T3 (da) 2011-01-24

Family

ID=36677174

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06748900.5T DK1869020T3 (da) 2005-03-29 2006-03-29 Heteroarylureaderivater egnet til inhibering af CHK1

Country Status (32)

Country Link
US (1) US8093244B2 (da)
EP (2) EP1869020B1 (da)
JP (2) JP5117374B2 (da)
KR (2) KR20090031459A (da)
CN (2) CN102219784A (da)
AR (1) AR056645A1 (da)
AT (1) ATE490248T1 (da)
AU (1) AU2006230337B2 (da)
BR (1) BRPI0609667A2 (da)
CA (1) CA2602199C (da)
CR (1) CR9395A (da)
CY (1) CY1111240T1 (da)
DE (1) DE602006018590D1 (da)
DK (1) DK1869020T3 (da)
EA (1) EA011287B1 (da)
ES (1) ES2356068T3 (da)
HK (1) HK1119670A1 (da)
HR (1) HRP20100678T1 (da)
IL (1) IL185481A0 (da)
MA (1) MA29439B1 (da)
MX (1) MX2007012116A (da)
NO (1) NO20074944L (da)
NZ (1) NZ561458A (da)
PL (1) PL1869020T3 (da)
PT (1) PT1869020E (da)
RS (1) RS51616B (da)
SI (1) SI1869020T1 (da)
TN (1) TNSN07369A1 (da)
TW (1) TWI375559B (da)
UA (1) UA92164C2 (da)
WO (1) WO2006105262A1 (da)
ZA (1) ZA200707715B (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA95310C2 (ru) * 2006-10-20 2011-07-25 Айкос Корпорейшен Композиция, содержащая ингибитор chk1 и циклодекстрин, для лечения рака
CN101200429B (zh) * 2006-12-13 2012-08-22 上海睿智化学研究有限公司 2-硝基-4,5-二卤代苯酚类和2-氨基-4,5-二卤代苯酚类及其盐及其合成方法
GB201008005D0 (en) 2010-05-13 2010-06-30 Sentinel Oncology Ltd Pharmaceutical compounds
CN105764501A (zh) 2013-07-26 2016-07-13 现代化制药公司 改善比生群治疗效益的组合物
NZ727399A (en) 2014-06-17 2022-07-29 Vertex Pharma Method for treating cancer using a combination of chk1 and atr inhibitors
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
MX395066B (es) 2015-09-30 2025-03-24 Vertex Pharma Método para tratar cáncer usando una combinación de agentes que dañan el adn e inhibidores de proteína relacionada con ataxia telangiectasia y rad3 (atr).
AU2016391377B2 (en) 2016-02-04 2019-07-18 Pharmaengine, Inc. 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (Chk1) inhibitors, and their preparations and applications
WO2017157825A1 (en) 2016-03-15 2017-09-21 F. Hoffmann-La Roche Ag Combinations of lsd1 inhibitors for use in the treatment of solid tumors
KR20190130621A (ko) * 2017-03-31 2019-11-22 시애틀 지네틱스, 인크. Chk1 저해제와 wee1 저해제의 조합물
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
US20210332136A1 (en) * 2020-03-13 2021-10-28 Research Development Foundation Methods for diagnosing and treating cancers

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4293552A (en) 1978-02-27 1981-10-06 Eli Lilly And Company Novel 1-(mono-o-substituted benzoyl)-3-(substituted pyrazinyl) ureas
US6174993B1 (en) 1997-05-21 2001-01-16 The Children's Medical Center Corp. Short peptides which selectively modulate the activity of serine/threonine kinases
GB9718952D0 (en) 1997-09-05 1997-11-12 Medical Res Council Mammalian chk1 effector cell cycle checkpoint protein kinase materials and methods
US6218109B1 (en) 1997-09-05 2001-04-17 Baylor College Of Medicine Mammalian checkpoint genes and proteins
AU9691198A (en) 1997-10-06 1999-04-27 Basf Aktiengesellschaft Indeno{1,2-c}-, naphtho{1,2-c}- and benzo{6,7}cyclohepta{1,2-c}pyrazole derivatives
EP1135135A4 (en) 1998-09-18 2006-08-09 Smithkline Beecham Corp CHK1 KINASE INHIBITORS
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
WO2001057206A2 (en) 2000-02-03 2001-08-09 Ribozyme Pharmaceuticals, Inc. Method and reagent for the inhibition of checkpoint kinase-1 (chk 1) enzyme
US6495586B2 (en) 2000-02-25 2002-12-17 The Regents Of The University Of California Scytonemin and methods of using thereof
US6211164B1 (en) 2000-03-10 2001-04-03 Abbott Laboratories Antisense oligonucleotides of the human chk1 gene and uses thereof
US6534691B2 (en) 2000-07-18 2003-03-18 E. I. Du Pont De Nemours And Company Manufacturing process for α-olefins
ATE295354T1 (de) 2000-08-18 2005-05-15 Agouron Pharma Heterozyklische-hydroximino-fluorene und ihre verwendung zur inhibierung von proteinkinasen
EP1379524A2 (en) 2001-01-26 2004-01-14 Pharmacia Italia S.p.A. Chromane derivatives, process for their preparation and their use as antitumor agents
UA76977C2 (en) 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
EP1401831A1 (en) 2001-07-03 2004-03-31 Chiron Corporation Indazole benzimidazole compounds as tyrosine and serine/threonine kinase inhibitors
DE60229975D1 (de) 2001-10-04 2009-01-02 Smithkline Beecham Corp Nf-kb-inhibitoren
WO2003029241A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
WO2003028731A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
WO2003028724A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
BR0213734A (pt) 2001-10-30 2004-10-19 Pharmacia Corp Derivados de carboxamida heteroaromático para o tratamento de inflamação
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
US20030119839A1 (en) 2001-12-13 2003-06-26 Nan-Horng Lin Protein kinase inhibitors
EP1501831A1 (en) 2002-04-26 2005-02-02 Warner-Lambert Company Llc Inhibitors of checkpoint kinases (wee1 and chk1)
US7202244B2 (en) * 2002-05-29 2007-04-10 Millennium Pharmaceuticals, Inc. Chk-1 inhibitors
US20040034038A1 (en) 2002-08-13 2004-02-19 Goaquan Li Urea kinase inhibitors
US7056925B2 (en) * 2002-08-13 2006-06-06 Abbott Laboratories Urea kinase inhibitors
JP4613130B2 (ja) 2002-08-23 2011-01-12 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド ベンゾイミダゾールキノリノンおよびそれらの使用
MXPA05005547A (es) 2002-11-28 2005-07-26 Schering Ag Pirimidinas inhibidoras de chk, pdk y akt, su produccion y uso como agentes farmaceuticos.
KR100697746B1 (ko) 2003-01-09 2007-03-22 화이자 인코포레이티드 키나제 저해제로서의 디아제피노인돌 유도체
AU2005267185A1 (en) * 2004-06-25 2006-02-02 Icos Corporation Bisarylurea derivatives useful for inhibiting CHK1
CA2679908A1 (en) 2009-09-23 2011-03-23 Shell Internationale Research Maatschappij B.V. Closed loop solvent extraction process for oil sands
CN104407475B (zh) 2014-12-04 2017-04-05 厦门天马微电子有限公司 液晶显示面板

Also Published As

Publication number Publication date
PL1869020T3 (pl) 2011-05-31
HK1119670A1 (en) 2009-03-13
PT1869020E (pt) 2010-12-23
CY1111240T1 (el) 2015-06-11
ES2356068T3 (es) 2011-04-04
MX2007012116A (es) 2008-04-08
CA2602199C (en) 2013-09-10
CN102219784A (zh) 2011-10-19
AR056645A1 (es) 2007-10-17
AU2006230337B2 (en) 2011-10-27
DE602006018590D1 (de) 2011-01-13
US20090143357A1 (en) 2009-06-04
KR20090031459A (ko) 2009-03-25
UA92164C2 (ru) 2010-10-11
TNSN07369A1 (en) 2008-12-31
EA011287B1 (ru) 2009-02-27
HRP20100678T1 (hr) 2011-02-28
TW200722090A (en) 2007-06-16
TWI375559B (en) 2012-11-01
JP2009227682A (ja) 2009-10-08
ZA200707715B (en) 2009-09-30
EP1869020A1 (en) 2007-12-26
CN101151259B (zh) 2011-06-15
KR100912998B1 (ko) 2009-08-20
KR20070107178A (ko) 2007-11-06
CR9395A (es) 2008-03-31
AU2006230337A1 (en) 2006-10-05
US8093244B2 (en) 2012-01-10
IL185481A0 (en) 2008-01-06
BRPI0609667A2 (pt) 2010-04-20
CN101151259A (zh) 2008-03-26
ATE490248T1 (de) 2010-12-15
JP5117374B2 (ja) 2013-01-16
NO20074944L (no) 2007-10-24
CA2602199A1 (en) 2006-10-05
RS51616B (en) 2011-08-31
EA200702094A1 (ru) 2008-02-28
EP1869020B1 (en) 2010-12-01
SI1869020T1 (sl) 2011-02-28
NZ561458A (en) 2011-03-31
JP2008535830A (ja) 2008-09-04
MA29439B1 (fr) 2008-05-02
EP2330105A1 (en) 2011-06-08
WO2006105262A1 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
DK1737461T3 (da) Carbolin-derivater til inhibering af angiogenese
DK1869020T3 (da) Heteroarylureaderivater egnet til inhibering af CHK1
DK1928454T3 (da) Pyridonderivater til modulering af stress-aktiveret proteinkinasesystem
DK1919907T5 (da) Heterocyklisk forbindelse
NL2000537A1 (nl) Aminederivaten.
ATE475662T1 (de) Dihydropyrazolopyrimidinonderivate
ATE483711T1 (de) Spiroindolinonderivate
ATE512135T1 (de) Spiroindolinonderivate
ATE520670T1 (de) Pyridazinderivate
DK2865422T3 (da) Alpha-msh-derivater til behandling af fotodermatoser
DK2035394T3 (da) 2-pyrazincarboxamidderivater
DK1948678T3 (da) Forbindelser til enzyminhibering
ATE512953T1 (de) Heterocyclische verbindungen
ATE400271T1 (de) Aryl-pyridinderivate als 11-beta-hsd1-hemmer
ATE452132T1 (de) Benzimidazolthiophenverbindungen als plk- inhibitoren
DE602006010581D1 (de) 4-phenyl-6-substituierte pyrimidin-2-carbonitrilderivate
ATE467623T1 (de) Diazepan-acetamidderivate als selektive 11-hsd1- hemmer
ATE420076T1 (de) Indozolonderivate als 11b-hsd1-inhibitoren
ATE487718T1 (de) Substituierte bizyklische pyrimidonderivate
BRPI0720547A2 (pt) Inibidores de metaloprotease derivada de heterocíclico
ATE485294T1 (de) Azaindol-2-carboxamid-derivate
DK2213654T3 (da) Fremgangsmåde til fremstilling af 2-amino-5-brombenzamid derivater
ATE527255T1 (de) Aryl-isoxazol-4-yl-imidazol-derivate
DK2086968T3 (da) 5-hydroxymethyl-oxazolidin-2-on-derivater
DK1971588T3 (da) Tiglien-3-onderivater